缓释地塞米松玻璃体内植入剂治疗静止期葡萄膜炎黄斑囊样水肿的前瞻性评估
这项前瞻性干预性病例系列纳入10例葡萄膜炎静止期但黄斑囊样水肿持续存在的患者,基线时给予地塞米松玻璃体内植入剂,每月随访一年,水肿复发时再次注射。第90天最佳矫正视力平均改善14.4个字母(P=0.0003),中心子区视网膜厚度平均下降140微米(P=0.008);第360天视力平均改善16.5个字母(P=0.006),厚度平均下降158微米(P=0.002)。作者认为该植入剂可能对静止期葡萄膜炎的持续性黄斑囊样水肿有效。
要点
- 第90天最佳矫正视力较基线平均改善14.4个字母(P=0.0003),70%患者改善≥10个字母,50%患者改善≥15个字母。
- 第90天中心子区视网膜厚度较基线平均下降140微米(P=0.008),按需再治疗后改善维持至第360天。
- 1例出现眼压>25 mmHg(局部药物控制),2例有晶状体眼(2/8;25%)晶状体混浊加重需白内障摘除。
核心结论
- 地塞米松玻璃体内植入剂可能对静止期葡萄膜炎的持续性黄斑囊样水肿有效。
研究设计与样本
- 前瞻性干预性病例系列,纳入10例葡萄膜炎静止期且黄斑囊样水肿持续存在的患者,基线时给予地塞米松玻璃体内植入剂,每月随访一年,水肿复发时再次注射。
主要发现
- 第90天最佳矫正视力较基线平均改善14.4个字母(P=0.0003),70%患者改善≥10个字母,50%患者改善≥15个字母。
- 第90天中心子区视网膜厚度较基线平均下降140微米(P=0.008)。
- 按需再治疗后改善维持至第360天,最佳矫正视力较基线平均改善16.5个字母(P=0.006),中心子区视网膜厚度较基线平均下降158微米(P=0.002)。
- 1例出现眼压>25 mmHg,经局部药物治疗控制。
- 2例有晶状体眼(2/8;25%)晶状体混浊加重,需行白内障摘除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation. METHODS: In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred. The primary outcome measure was best-corrected visual acuity (BCVA) at day 90. RESULTS: At day 90, mean improvement from baseline BCVA was 14.4 letters (P = 0.0003), 70% of patients had a ≥10 letter BCVA improvement, 50% of patients had a ≥15 letter BCVA improvement, and the mean decrease from baseline central subfield retinal thickness was 140 μm (P = 0.008). Improvements were maintained through day 360 with retreatment as needed. At day 360, mean improvement in BCVA was 16.5 letters (P = 0.006) and the mean decrease in central subfield retinal thickness was 158 μm (P = 0.002). One patient experienced intraocular pressure >25 mmHg (managed with topical medication). Two phakic patients (2/8; 25%) had worsening of lens opacity requiring cataract extraction. CONCLUSION: Dexamethasone intravitreal implant may be an effective treatment for patients with persistent cystoid macular edema in quiescent uveitis.
引用
- Khurana RN, Bansal AS, Chang LK, et al. PROSPECTIVE EVALUATION OF A SUSTAINED-RELEASE DEXAMETHASONE INTRAVITREAL IMPLANT FOR CYSTOID MACULAR EDEMA IN QUIESCENT UVEITIS. Retina. 2017. PMID: 27893624. doi:10.1097/IAE.0000000000001406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。